Icosagen
 Icosagen Homepage |
Icosagen (Estonia) is a research-driven contract research provider for biopharmaceutical and biotechnology industries that deftly adapts to market forces and current trends, and is always guided by the needs of its customers. A portfolio of off-the-shelf products, such as antibodies, proteins, ELISA kits, etc., and quality control services in the field of natural rubber allergen testing and food quality control, are also part of the activities of Icosagen AS. |
Product News
| Icosagen has released 5 new protein products for SARS-CoV-2 variant strains P-314-100 SARS-CoV-2 Spike RBD2 South Africa VOC 501.V2 South Africa Variant P-315-100 SARS-CoV-2 Spike RBD2 Brazil P1 Brazil Variant P-316-100 SARS-CoV-2 Trimeric Spike South Africa VOC 501.V2 South Africa Variant Stable Trimer P-317-100 SARS-CoV-2 Trimeric Spike UK VOC 202012/01 UK Variant Stable Trimer P-318-100 SARS-CoV-2 Trimeric Spike Brazil P1 Brazil Variant Stable Trimer |
|
| Icosagen has released 3 new protein products for SARS-CoV-2 Research P-309-100 SARS-CoV-2 Trimeric Spike Stable Trimer P-310-100 SARS-CoV-2 Spike S1 UK VOC 202012/01 UK Variant P-311-100 SARS-CoV-2 Spike RBD2 UK VOC 202012/01 UK Variant |
| Menu |
| 1 Technology 1.1 HybriFree Technology 1.2 QMCF Technology 2 Products 2.1 Antibodies 2.2 Proteins 2.3 ELISA Kits 2.4 Transfection Reagents 3 Services 3.1 Recombinant Antibody Production 3.2 Antibody Development 3.3 Protein Production 3.4 Expression of Membrane Proteins |
Technology
HybriFree Technology
The proprietary HybriFree method is used for the discovery of monoclonal antibodies from rabbits and chickens. This includes the capture of antibody-producing cells, cloning of VH/VL sequences and construction of human IgG minilibraries for screening. The antibody expression vectors constructed during antibody discovery can be directly used for the manufacturing in Chinese hamster ovary (CHO) cells.
Benefits of the HybriFree Technology
- Immunization of wild type rabbits and chickens provides great diversity with broad epitope coverage, and picomolar affinities without affinity maturation
- HybriFree in vivo B cell approach captures antibodies with optimal biochemical properties leading to good developability
- Good manufacturability of the antibodies is achieved by using CHO cells for the expression of IgG minilibraries that are developed directly from B cells
- Greater evolutionary distance of chicken yields greater immunogenicity against conserved targets compared to mice
- HybriFree antibody discovery platform is further powered by Icosagen’s patented QMCF expression technology and extensive biochemical competence resulting in high quality antigen production
- Icosagen has a proprietary VLP-technology for high level expression of membrane proteins including GPCRs
Benefits of choosing rabbit or chicken for immunization
 |
Mouse Slow immunization Normal affinity Industry standard |
 |
Chicken Fastest immunization High affinity The best for conserved targets |
 |
Rabbit Fast immunization Highest affinity The best for small molecules |
QMCF Technology
|
QMCF technology for recombinant protein production is based on replication and stable maintenance of expression vectors in CHO cells, in conjunction with specifically optimized culture conditions. Fast and cost-effective production of recombinant proteins is accomplished by engineering CHO cells to express two viral factors:
|
 |
Benefits to the clients
- Recombinant protein production (up to 50 L scale) is managed by PhD-level scientists that guarantee smooth flow of projects (including difficult to express proteins) and transparent communication with clients, supported by detailed project reports
- Cloning of DNA expression vectors are done with rapid one-step ligase independent method, which is based on Gibson assembly
- Patented QMCF expression technology in CHO and HEK293 cells provides cost-effectiveness and scalability
- QMCF CHO cell pools and production cell banks for the commercial supply of diagnostic antibodies can be generated in 10 days
- Wide range methods for QC analysis are available, including protein concentration, Western blot, PAGE, LabChip, IEF (to determine isoelectric point), analytical SEC (to determine aggregation level), LAL test (to determine endotoxin levels), Octet system (to determine affinity and kinetics), FLOW analysis, DLS (to determine particle size), HILIC HPLC (to determine afucosylation level), LC-MS and LC-MS/MS (to determine proteomic properties)
- Capabilities to develop methods for the purification of native proteins without tags
Icosagen’s protein production service is based on the QMCF technology that is a robust mammalian expression system for recombinant proteins, delivering up to 1.5 g of antibody per litre of media. Expression vectors are constructed and transfected into CHO cells with our proprietary transfection reagent 007. Proteins are purified from the media with the method that is best suited for the protein of interest. Produced proteins and antibodies have high grade of purity, low endotoxin level and native folding. Deliverables include detailed reports.
Products
Antibodies
| Nucleocapsid Protein SARS-CoV-2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-350-100 | Nucleocapsid protein SARS-CoV-2 | Chicken polyclonal | IgY |
| R1-147-100 | Nucleocapsid protein SARS-CoV-2 | Recombinant human monoclonal | human IgG1-lambda |
| R1-148-100 | Nucleocapsid protein SARS-CoV-2 | Recombinant human monoclonal | human IgG1-lambda |
| R1-149-100 | Nucleocapsid protein SARS-CoV-2 | Recombinant human monoclonal | human IgG1-lambda |
| R1-178-100 | Nucleocapsid protein SARS-CoV-2 | Recombinant human monoclonal | Human IgG1-kappa |
| R1-179-100 | Nucleocapsid protein SARS-CoV-2 | Recombinant human monoclonal | Human IgG1-kappa |
| Spike SARS-CoV-2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| R1-151-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-kappa |
| R1-156-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| R1-157-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-kappa |
| R1-158-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| R1-159-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-kappa |
| R1-163-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| R1-164-100 | RBD protein SARS-CoV-2 | Recombinant human monoclonal | Human IgG1-lambda |
| R1-169-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| R1-170-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| R1-180-100 | SARS-CoV-2 virus | Recombinant human monoclonal | Human IgG1-lambda |
| BPV Type 1 E2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A1-100-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-101-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-150-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-151-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-152-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-153-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-154-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| A1-155-100 | BPV type 1 E2 | Mouse monoclonal | IgG |
| Ebolavirus GP Protein100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-100-100 | Ebolavirus GP protein | Rabbit polyclonal | IgG |
| A2-101-100 | Ebolavirus GP protein | Monoclonal: rabbit scFv, human Fc | hIgG1 scFv-Fc |
| HPV-18 E2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-401-100 | HPV-18 E2 | Mouse monoclonal | IgG |
| HPV-11 E2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-402-100 | HPV-11 E2 | Mouse monoclonal | IgG1 |
| A2-403-100 | HPV-11 E2 | Mouse monoclonal | IgG1 |
| HPV-11 E7100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-404-100 | HPV-11 E7 | Mouse monoclonal | IgG2a |
| A2-405-100 | HPV-11 E7 | Mouse monoclonal | IgG2a |
| HPV-18 E7100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-406-100 | HPV-18 E7 | Mouse monoclonal | IgG1 |
| A2-407-100 | HPV-18 E7 | Mouse monoclonal | IgG1 |
| HCV 1b NS5B100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-420-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-421-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-422-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-423-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-424-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-425-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-426-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-427-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| A2-428-100 | HCV 1b NS5B | Mouse monoclonal | IgG1 |
| C2-424-100 | HCV 1b NS5B | Partially humanized monoclonal | IgG1 |
| HIV-1 Nef100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-801-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-802-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-803-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-804-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-806-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-807-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-809-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| A2-811-100 | HIV-1 Nef | Mouse monoclonal | IgG1 |
| HIV-1 Tat100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-821-100 | HIV-1 Tat | Mouse monoclonal | IgG2b |
| A2-822-100 | HIV-1 Tat | Mouse monoclonal | IgG1 |
| A2-823-100 | HIV-1 Tat | Mouse monoclonal | IgG1 |
| A2-825-100 | HIV-1 Tat | Mouse monoclonal | IgM |
| A2-826-100 | HIV-1 Tat | Mouse monoclonal | IgG3 |
| A2-827-100 | HIV-1 Tat | Mouse monoclonal | IgG2b |
| HIV-1 Rev100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-832-100 | HIV-1 Rev | Mouse monoclonal | IgG1 |
| HIV-1 p24100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-851-100 | HIV-1 p24 | Mouse monoclonal | IgG2a |
| A2-854-100 | HIV-1 p24 | Mouse monoclonal | IgG1 |
| A2-855-100 | HIV-1 p24 | Mouse monoclonal | IgG1 |
| A2-856-100 | HIV-1 p24 | Mouse monoclonal | IgG2b |
| A2-857-100 | HIV-1 p24 | Mouse monoclonal | IgG2a |
| A2-858-100 | HIV-1 p24 | Mouse monoclonal | IgG1 |
| A2-859-100 | HIV-1 p24 | Mouse monoclonal | IgG1 |
| C-851-100 | HIV-1 p24 | Partially humanized monoclonal | IgG1 |
| MLV p30100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A1-910-100 | MLV p30 | Rabbit polyclonal | IgG |
| A2-301-100 | MLV p30 | Mouse monoclonal | IgG |
| SIV-1 Nef100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-817-100 | SIV-1 Nef | Mouse monoclonal | IgG1 |
| Human GDNF100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 315-100 | Human GDNF | Mouse monoclonal | murine IgG1 |
| Human Artemin100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 323-100 | Human Artemin | Mouse monoclonal | IgG1 |
| 324-100 | Human Artemin | Mouse monoclonal | IgG1 |
| 325-100 | Human Artemin | Mouse monoclonal | IgG1 |
| 326-100 | Human Artemin | Mouse monoclonal | IgG1 |
| Human BDNF100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 327-100 | Human BDNF | Mouse monoclonal | IgG1 |
| 328-100 | Human BDNF | Mouse monoclonal | IgG1 |
| 329-100 | Human BDNF | Mouse monoclonal | IgG2b |
| Human CDNF100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 300-100 | Human CDNF | Rabbit polyclonal | IgG |
| 301-100 | Human CDNF | Mouse monoclonal | IgG1 |
| 302-100 | Human CDNF | Mouse monoclonal | IgG1 |
| Human MANF100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 310-100 | Human MANF | Rabbit polyclonal | IgG |
| 311-100 | Human MANF | Mouse monoclonal | IgG1 |
| 341-100 | Human MANF | Recombinant monoclonal antibody | mouse IgG2a |
| 342-100 | Human MANF | Recombinant monoclonal antibody | mouse IgG2a |
| 343-100 | Human MANF | Recombinant monoclonal antibody | mouse IgG2a |
| Human GFRa-1100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 303-100 | Human GFRa-1 | Chicken polyclonal | IgY |
| Human GFRa-2100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 304-100 | Human GFRa-2 | Chicken polyclonal | IgY |
| Human GFRa-3100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 305-100 | Human GFRa-3 | Chicken polyclonal | IgY |
| Human GFRa-4100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 308-100 | Human GFRa-4 | Chicken polyclonal | IgY |
| Human Neurturin100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 307-100 | Human Neurturin | Rabbit polyclonal | IgG |
| 320-100 | Human Neurturin | Mouse monoclonal | IgG1 |
| 321-100 | Human Neurturin | Mouse monoclonal | IgG1 |
| 322-100 | Human Neurturin | Mouse Monoclonal | IgG1 |
| Human RET100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 306-100 | Human RET | Chicken polyclonal | IgY |
| Hev b1100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A3-700-100 | Hev b1 | Mouse monoclonal | IgG2a |
| A3-701-100 | Hev b1 | Mouse monoclonal | IgG1 |
| Hev b3100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A3-704-100 | Hev b3 | Mouse monoclonal | IgG1 |
| A3-705-100 | Hev b3 | Mouse monoclonal | IgG1 |
| Hev b5100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A3-707-100 | Hev b5 | Mouse monoclonal | IgG1 |
| A3-708-100 | Hev b5 | Mouse monoclonal | IgG2b |
| Hev b6.02100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A3-709-100 | Hev b6.02 | Mouse monoclonal | IgG1 |
| A3-710-100 | Hev b6.02 | Mouse monoclonal | IgG1 |
| Rabbit Anti-Chicken Polyclonal Antibodies100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 903-100 | chicken IgY | Rabbit polyclonal, HRP conjugate | IgG |
| 904-100 | chicken IgY | Rabbit polyclonal, DyLight 488 conjugate | IgG |
| 905-100 | chicken IgY | Rabbit polyclonal, DyLight 549 conjugate | IgG |
| Goat Anti-Mouse Polyclonal Antibodies100 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A1-900-100 | Mouse IgG fraction | Goat polyclonal HRP-conjugate | IgG |
| A1-901-100 | Mouse IgG fraction | Goat polyclonal FITC-conjugate | IgG |
| A1-902-100 | Mouse IgG fraction | Goat polyclonal, AP-conjugate | IgG |
| Human C-C Motif Chemokine 20 (CCL20)100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 601-100 | Human C-C motif chemokine 20 (CCL20) | Mouse monoclonal | IgG1 |
| Human Elafin100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 630-100 | Human Elafin | Mouse monoclonal | IgG1 |
| Human Interferon Lambda-4 (IFNL4)100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 600-100 | Human Interferon lambda-4 (IFNL4) | Rabbit polyclonal | |
| Human S100-A8100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 620-100 | Human S100-A8 | Mouse monoclonal | IgG1 |
| Human S100-A9100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 610-100 | Human S100-A9 | Mouse monoclonal | IgG1 |
| Human Cardiac Troponin I100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 102-100 | Human cardiac troponin I | Mouse monoclonal | IgG1 |
| 103-100 | Human cardiac troponin I | Mouse monoclonal | IgG1 |
| 104-100 | Human cardiac troponin I | Mouse monoclonal | IgG1 |
| 105-100 | Human cardiac troponin I | Mouse monoclonal | IgG1 |
| Recombinant Human Cardiac Troponin Complex100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| R1-126-100 | Recombinant human cardiac troponin complex | Recombinant human monoclonal | Human IgG2-lambda |
| Anti-HEL Human IgG1 Isotype Control1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| R1-146-000 | Lysozyme from chicken egg white | Recombinant human monoclonal | IgG1 |
| His-6 Tag100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-501-100 | His-tag | Mouse monoclonal | IgG2b |
| Bovine DNase I100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 400-100 | Bovine DNase I | Rabbit polyclonal | IgG |
| 404-100 | Bovine DNase I | Mouse monoclonal | IgG1 |
| 405-100 | Bovine DNase I | Mouse monoclonal | IgG1 |
| Human Ribonuclease 7100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 406-100 | Human Ribonuclease 7 | Mouse monoclonal | IgG1 |
| 407-100 | Human Ribonuclease 7 | Mouse monoclonal | IgG1 |
| 408-100 | Human Ribonuclease 7 | Mouse monoclonal | IgG1 |
| Human Ribonuclease 8100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| 430-100 | Human Ribonuclease 8 | Rabbit polyclonal | IgG |
| Human Laminin a4100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-601-100 | Human laminin a4 | Mouse monoclonal | IgG1 |
| A2-604-100 | Human laminin a4 | Mouse monoclonal | IgG1 |
| A2-607-100 | Human laminin a4 | Mouse monoclonal | IgG1 |
| Human Laminin a5100 μg/500 μg/1000 μg | |||
| Catalogue # | Immunogen | Clonality | Class |
| A2-610-100 | Human laminin a5 | Mouse monoclonal | IgG1 |
Proteins
| SARS-CoV-2100 μg/500 μg/1000 μg | ||
| Catalogue # | Product Name | Host |
| P-301-100 | SARS-CoV-2 Nucleocapsid-His Protein | CHO-based cell line (expressed by QMCF Technology) |
| P-302-100 | Human recombinant ACE2-His Protein | CHO-based cell line (expressed by QMCF Technology) |
| P-303-100 | SARS-CoV-2 S1 RBD | CHO-based cell line (expressed by QMCF Technology) |
| P-305-100 | SARS-CoV-2 Spike S1 | CHO-based cell line (expressed by QMCF Technology) |
| P-306-100 | SARS-CoV-2 Spike S2 ECD-His | CHO-based cell line (expressed by QMCF Technology) |
| P-307-100 | SARS-CoV-2 S1 RBD2 | CHO-based cell line (expressed by QMCF Technology) |
| P-308-100 | Human recombinant ACE2-hFc | CHO-based cell line (expressed by QMCF Technology) |
| P-309-100 | SARS-CoV-2 Trimeric Spike | CHO-based cell line (expressed by QMCF Technology) |
| P-310-100 | SARS-CoV-2 Spike S1 UK VOC 202012/01 | CHO-based cell line (expressed by QMCF Technology) |
| P-311-100 | SARS-CoV-2 Spike RBD2 UK VOC 202012/01 | CHO-based cell line (expressed by QMCF Technology) |
| P-314-100 | SARS-CoV-2 Spike RBD2 South Africa VOC 501.V2 | CHO-based cell line (expressed by QMCF Technology) |
| P-315-100 | SARS-CoV-2 Spike RBD2 Brazil P1 | CHO-based cell line (expressed by QMCF Technology) |
| P-316-100 | SARS-CoV-2 Trimeric Spike South Africa VOC 501.V2 | CHO-based cell line (expressed by QMCF Technology) |
| P-317-100 | SARS-CoV-2 Trimeric Spike UK VOC 202012/01 | CHO-based cell line (expressed by QMCF Technology) |
| P-318-100 | SARS-CoV-2 Trimeric Spike Brazil P1 | CHO-based cell line (expressed by QMCF Technology) |
| Others10 μg/50 μg/100 μg | ||
| Catalogue # | Product Name | Host |
| P-100-100 | CDNF, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-101-100 | MANF, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-102-100 | Artemin, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-103-100 | GDNF, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-104-100 | NGF, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-105-100 | BDNF, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-120-100 | GFRA-1-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-121-100 | GFRA-2-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-122-100 | GFRA-3-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-123-100 | GFRA-4-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-124-100 | RET-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-200-100 | DNase I, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-201-100 | DNase I, bovine recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-300-100 | Zaire Ebolavirus envelope glycoprotein | Mammalian expression system |
| P-400-100 | Recombinant human RNase 7 | CHO-based cell line (expressed by QMCF Technology) |
| P-402-100 | CD48, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-403-100 | CD48, mouse recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-404-100 | 2B4-His, human recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-405-100 | 2B4-His, mouse recombinant | CHO-based cell line (expressed by QMCF Technology) |
| P-500-100 | Recombinant murine leukemia virus p30 protein | E. coli |
| P-600-100 | Human Cardiac Troponin complex | CHO-based cell line (expressed by QMCF Technology) |
ELISA Kits
| SARS-CoV-296-well plate | |||||
| Catalogue # | Antibodies Against | Detectable Antibodies | Substrate | ||
| K5-001-096 | SARS-CoV-2 | IgG, IgM | Antigen-coated (S1 and N) microplate wells | ||
| Natural Rubber Latex Allergen96-well plate | |||||
| Catalogue # | Product Name | Limit of Detection | Detection Range | Manual | MSDS |
| K3-350-020 | FITkit® Hev b 1 | ⩽ 2.0 μg/L | 10-1000 μg/L |  |
|
| K3-350-030 | FITkit® Hev b 3 | ⩽ 2.0 μg/L | 10-1000 μg/L | |
|
| K3-350-040 | FITkit® Hev b 5 | ⩽ 1.5 μg/L | 5-100 μg/L | |
|
| K3-350-010 | FITkit® Hev b 6.02 (Hevein) | ⩽ 1.5 μg/L | 5-200 μg/L | |
|
| K3-350-050 | ELISA Kit 4 Latex Allergens | Hev b 1: 10-1000 µg/L Hev b 3: 10-1000 µg/L Hev b 5: 5-100 µg/L Hev b 6.02: 5-200 µg/L |
|
||
| Others96-well plate | |||||
| Catalogue # | Product Name | Limit of Detection | Detection Range | Manual | MSDS |
| K2-001-096 | Human CDNF ELISA Kit | 1-8 pg/mL | 15-960 pg/mL | |
|
| K2-002-096 | Human Neurturin ELISA Kit | 5-13 pg/mL | 50-1600 pg/mL | |
|
| K2-003-096 | Human Artemin ELISA Kit | 2-8 pg/mL | 30-1920 pg/mL | |
|
| K2-004-096 | Human MANF ELISA Kit | 30-75 pg/mL | 0.25-16 ng/mL | |
|
| K4-001-096 | Human RNase 7 ELISA kit | 1-4 pg/mL | 10-640 pg/mL | |
|
| K4-002-096 | Human CD48 ELISA Kit | 2-8 pg/mL | 25-1600 pg/mL | |
|
| K4-003-096 | Mouse CD48 ELISA Kit | 6-16 pg/mL | 50-3200 pg/mL | |
|
Transfection Reagents
| Catalogue # | Description |
| R007-P001 | Reagent 007, 1 mg (powder) |
| R007-P010 | Reagent 007, 10 mg (powder) |
| TC-010-000 | Salmon Sperm Carrier DNA for transfection (10mg/mL) 1mL |
Services
Recombinant Antibody Production
Icosagen offers a broad range of tailored services for the development and production of recombinant antibodies, including complex antibody formats.
Our customers benefit from our cost effective QMCF Expression Technology that is based on the replication, and stable maintenance of the expression vectors in CHO cells, in conjunction with specifically optimized culture conditions for the recombinant antibody production.
There are two options for recombinant antibody production by using QMCF Technology:
- Enhanced transient production of recombinant antibodies is used to deliver up to hundreds of milligrams of purified antibody within 3-4 weeks starting from vector cloning.
- Stable episomal production is used to scale up the production volumes up to 40 liters cost effectively, and to deliver multiple gram quantities of purified antibody. In this case, also episomal production cell bank can be generated, which allows to omit transfection completely when repetitive and constant supply of the same antibody is required with consistent reproducibility.
Antibody Development
Icosagen offers the following antibody development services:
- Monoclonal antibody development from chicken and rabbits by using our proprietary HybriFree technology that is based on the VH/VL cloning from B-cells
- Hybridoma-based antibody development from mice
- Polyclonal antibody development from chicken and rabbits
Protein Production
Icosagen provides recombinant protein production services using proprietary CHO-based QMCF Technology in serum-free conditions. Customer benefits are a short production time and cost-efficiency.
We offer two options for protein production:
- Enhanced transient expression of recombinant proteins using high copy number transient pQMCF-T expression vectors. This option is fast, and a good fit for a small-scale pilot study to test the best expression conditions for your protein of interest.
- Production using stable episomal production pools for large-scale production using pQMCF expression vectors that are stably maintained in proliferating CHO cells. This option is scalable and suitable for the cost effective production in up to 40 liter scale, and to produce protein of interest in up to gram-scale.
Expression of Membrane Proteins
Production of VLP-s pseudotyped with membrane proteins
Icosagen produces VLPs pseudotyped with membrane proteins, such as ion-channels, receptors, viral glycoproteins, etc. For the formation of VLPs, we use retroviral (HIV-1 or MLV) and filoviral (ebola) proteins. VLPs could be produced in 293 or CHO-based QMCF cell lines.
- Fast and efficient production of VLPs pseudotyped with different receptors, ion-channels, viral glycoproteins, etc.
- Human-specific posttranslational modification pattern using 293-based cell line
Cell pool generation for membrane protein expression
Icosagen provides services for the fast development of CHO-based cell pools and cell lines, which express membrane proteins. The cell lines could be generated using QMCF Technology in 3 weeks, starting with the cloning of a protein of interest into a QMCF expression vector.
- Fast and efficient way to generate a stable population of cells expressing a protein of interest; for investigation of signal transduction, screening of active compounds for early stages of drug development
- Usage of CHO- or U2OS based adherent QMCF cell lines
- Feasible generation of expression cell banks
- Assay optimization and validation using Thermo Scientific ArrayScan VTI and appropriate Cellomics software
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.
info@tokyofuturestyle.com
TEL：029-851-9222 FAX：029-851-9220
